Table 1.
Summary of current clinical trials using antibody-based therapeutics to target hepatocellular carcinoma.
| Identifer | Drug(s) | Type | Target | Phase | Status |
|---|---|---|---|---|---|
| NCT01911273 | PF-03446962 | Mono | ALK-1 | II | Terminated |
| NCT01897038 | Onartuzumab with Sorafenib | Mono | c-Met/Tyrosine Kinases | I | Completed |
| NCT01008358 | Tremelimumab | Mono | CTLA4 | II | Completed |
| NCT00483405 | Cetuximab with chemotherapy | Mono | EGFR | II | Completed |
| NCT01375569 | TRC105 | Mono | Endoglin | II | Completed |
| NCT02560779 | TRC105 with Sorafenib | Mono | Endoglin/Tyrosine Kinases | II | Recruiting |
| NCT01507168 | GC33 | Mono | GPC3 | II | Completed |
| NCT00639509 | Cixutumumab | Mono | IGF-1R | II | Completed |
| NCT00906373 | Cixutumumab with Sorfenib | Mono | IGF-1R/Tyrosine Kinases | II | Completed |
| NCT02315066 | PF-04518600 | Mono | OX40(CD134) | I | Recruiting |
| NCT02595866 | Pembrolizumab | Mono | PD-1 | I | Recruiting |
| NCT00966251 | Pidilizumab | Mono | PD-1 | II | Terminated |
| NCT02423343 | Nivolumab with Galunisertib | Mono | PD-1/TGF-βR1 Kinases | II | Recruiting |
| NCT01102400 | MEDI-575 | Mono | PDGFRA | I | Completed |
| NCT02519348 | Durvalumab with Tremelimumab | Mono | PD-L1/CTLA4 | II | Recruiting |
| NCT01308723 | RO5323441 with Sorafenib | Mono | PGF/Tyrosine Kinases | I | Completed |
| NCT01258608 | Mapatumumab with Sorafenib | Mono | TRAIL-R1/Tyrosine Kinases | II | Ongoing |
| NCT00055692 | Bevacizumab | Mono | VEGF-A | II | Completed |
| NCT00467194 | Bevacizumab with Rapamycin | Mono | VEGF-A/mTor | I | Completed |
| NCT01010126 | Bevacizumab with Temsirolimus | Mono | VEGF-A/mTor | II | Ongoing |
| NCT00365391 | Bevacizumab with Erlotinib | Mono | VEGF-A/Tyrosine Kinases | II | Completed |
| NCT00867321 | Bevacizumab with Sorafenib | Mono | VEGF-A/Tyrosine Kinases | II | Completed |
| NCT01140347 | Ramucirumab | Mono | VEGF-R2 | III | Completed |
| NCT02069041 | Ramucirumab with Oxaliplatin | Mono | VEGF-R2/DNA | I | Recruiting |
| NCT02572687 | Ramucirumab with Durvalumab | Mono | VEGF-R2/PD-L1 | I | Recruiting |
| NCT01498952 | MEDI-573 with Sorafenib | Bispecific | IGF-I and IGF-II/Tyrosine Kinases | I | Completed |
| NCT01631552 | Sacituzumab Govitecan | ADC | TROP-2/Topoisomerase | II | Recruiting |
| NCT00829465 | Metuximab labeled with Iodine131 | ARC | CD147 | IV | Unknown |
| NCT02723942 | T cells expressing αGPC3 Antibody | CAR-T | GPC3 | II | Recruiting |
| NCT02632006 | T cells expressing PD-1 Antibody | CAR-T | PD-1 | II | Recruiting |
Abbreviations: ALK: Activin receptor-like kinase; ADC: Antibody drug conjugate; ARC: Antibody radioisotope conjugate; CAR-T: Chimeric antigen receptor T cell; CTLA: Cytotoxic T-lymphocyte associated protein; EGFR: Epidermal growth factor receptor; GPC3: Glypican-3; IGF(R): Insulin-like growth factor (receptor); Mono: Monoclonal; PD(-L): Programmed cell death protein (-ligand); PDGFRA: Platelet-derived growth factor receptor alpha chain; PGF: Placental growth factor; VEGF(R): Vascular endothelial growth factor (receptor).